EPCAM and hepatocellular carcinoma: A similar approach published by Julich-Haertel et al. [39] (Table 1) also showed EpCAM and CD147 increased on taMPs extracted from 172 patients with liver cancer (hepatocellular carcinoma, HCC; cholangiocarcinoma, CCA).